logo
  

Amended: CITIC Pacific To Buy Citic Limited In RMB 226.93 Bln In Cash And Stock Deal

amended: corrects company name to CITIC Pacific in the headline.

Citic Pacific Ltd. (CTPCY.PK) said that it signed a share transfer agreement with Citic group to buy 100% of Citic Limited, the main operating entity of Citic group, for RMB 226.93 billion in cash and stock deal.

As per the deal, CITIC Pacific will pay RMB 49.92 billion in cash and issue shares worth RMB 177.01 billion to CITIC Group.

The company said that the proposed value of new shares to be issued to CITIC Group amounts to RMB 177.01 billion, which equates to 16.58 billion shares. The new shares shall be priced at HK$13.48 per share, a premium of 25.86% to average closing price of CITIC Pacific's shares for the last 60 days up to and including the pricing date (24 March, 2014), being the last trading day before the company announced that it was in discussion with CITIC Group regarding the acquisition.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT